While 96% of the patients with true Li-Fraumeni tumor phenotype having concurrent LOH of wild-type TP53 and germline TP53 mutation, only 46% of non-Li-Fraumeni tumor phenotype patients have such double-hit TP53 loss [55]. Here, TP53 is linked to neoplasm.